Search Results - "Ognjenovic, Nevena B"

Lineage plasticity enables low-ER luminal tumors to evolve and gain basal-like traits by Mohamed, Gadisti Aisha, Mahmood, Sundis, Ognjenovic, Nevena B, Lee, Min Kyung, Wilkins, Owen M, Christensen, Brock C, Muller, Kristen E, Pattabiraman, Diwakar R

“…Stratifying breast cancer into specific molecular or histologic subtypes aids in therapeutic decision-making and predicting outcomes; however, these subtypes…”
Get full text

Phenotypic heterogeneity driven by plasticity of the intermediate EMT state governs disease progression and metastasis in breast cancer by Brown, Meredith S, Abdollahi, Behnaz, Wilkins, Owen M, Lu, Hanxu, Chakraborty, Priyanka, Ognjenovic, Nevena B, Muller, Kristen E, Jolly, Mohit Kumar, Christensen, Brock C, Hassanpour, Saeed, Pattabiraman, Diwakar R

“…The epithelial-to-mesenchymal transition (EMT) is frequently co-opted by cancer cells to enhance migratory and invasive cell traits. It is a key contributor to…”
Get full text

Limiting Self-Renewal of the Basal Compartment by PKA Activation Induces Differentiation and Alters the Evolution of Mammary Tumors by Ognjenovic, Nevena B., Bagheri, Meisam, Mohamed, Gadisti Aisha, Xu, Ke, Chen, Youdinghuan, Mohamed Saleem, Mohamed Ashick, Brown, Meredith S., Nagaraj, Shivashankar H., Muller, Kristen E., Gerber, Scott A., Christensen, Brock C., Pattabiraman, Diwakar R.

“…Differentiation therapy utilizes our understanding of the hierarchy of cellular systems to pharmacologically induce a shift toward terminal commitment. While…”
Get full text

Pharmacological induction of chromatin remodeling drives chemosensitization in triple-negative breast cancer by Bagheri, Meisam, Mohamed, Gadisti Aisha, Mohamed Saleem, Mohammed Ashick, Ognjenovic, Nevena B., Lu, Hanxu, Kolling, Fred W., Wilkins, Owen M., Das, Subhadeep, LaCroix, Ian S., Nagaraj, Shivashankar H., Muller, Kristen E., Gerber, Scott A., Miller, Todd W., Pattabiraman, Diwakar R.

“…Targeted therapies have improved outcomes for certain cancer subtypes, but cytotoxic chemotherapy remains a mainstay for triple-negative breast cancer (TNBC)…”
Get full text

Abstract 6430: Redefining therapy regimens for triple negative breast cancer - Exploiting the epigenetic effects of eribulin action by Bagheri, Meisam, Mohamed, Aisha, Ognjenovic, Nevena B., Pattabiraman, Diwakar R.

“…Abstract While the advent of targeted therapy has led to vast improvements in outcomes for certain types of breast cancer, the standard of care for triple…”
Get full text

Abstract P3-06-01: Eribulin alters the chromatin landscape to induce MET, attenuating metastatic progression and sensitizing breast tumors to subsequent chemotherapy by Pattabiraman, Diwakar R, Bagheri, Meisam, Ognjenovic, Nevena B, LaCroix, Ian S, Gerber, Scott A

“…Abstract Introduction: Two major hurdles faced in clinical cancer therapy are metastatic progression that results in the majority of cancer deaths, and…”
Get full text

Abstract 6251: Validation and implementation of whole-transcriptome sequencing assay into cancer care: An experience from a cancer center by Moran, Jillian A., Hughes, Edward G., Green, Donald C., Sukhadia, Shrey, Tsongalis, Gregory J., Allen, Samantha F., Tafe, Laura, Houde, Brianna, Ognjenovic, Nevena B., Barbuto, Jennifer N., Riano, Ivy, Shah, Parth

“…Abstract Introduction Transcriptome sequencing is a well-established diagnostic tool to characterize and quantify gene expression profiles and to detect fusion…”
Get full text

Abstract 1602: Lineage plasticity enables low ER luminal tumors to evolve and gain basal-like traits by Mohamed, Gadisti Aisha Nurulhijjah Binti, Ognjenovic, Nevena B., Mahmood, Sundis, Lee, Sarah Min Kyung, Christensen, Brock C., Muller, Kristen E., Pattabiraman, Diwakar R.

“…Abstract Stratifying breast cancer into specific molecular or histological subtypes aids in therapeutic decision-making and predicting outcomes, however, these…”
Get full text

Abstract 1785: Eribulin alters the chromatin landscape to induce MET, attenuating metastatic progression sensitizing breast tumors to subsequent chemotherapy by Bagheri, Meisam, Ognjenovic, Nevena B., Mohamed, Gadisti Aisha, LaCroix, Ian S., McCray, Andrew, Muller, Kristen E., Wang, Xiaofeng, Gerber, Scott A., Pattabiraman, Diwakar R.

“…Abstract Introduction: Two major hurdles faced in clinical cancer therapy are metastatic progression that results in the majority of cancer deaths, and…”
Get full text